YRRO Ltd agreed to acquire Hemcheck Sweden AB (publ) (OM:HEMC) in a reverse merger transaction for SEK 85.7 million on February 8, 2023. In exchange, Bio Vitos will receive 259,654,000 shares in Hemcheck, amounting to circa 88.3% of Hemcheck's share capital. It is anticipated that subject to all required shareholder and regulatory approvals, that Hemcheck will remain listed on the Nasdaq Stockholm.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1785 SEK | +0.85% | -7.99% | -25.00% |
1st Jan change | Capi. | |
---|---|---|
-25.00% | 4.77M | |
-1.89% | 12.5B | |
-9.59% | 7.67B | |
+21.82% | 5.36B | |
-1.31% | 5.26B | |
+0.02% | 4.57B | |
-50.89% | 3.15B | |
+6.42% | 2.59B | |
-10.02% | 2.06B | |
-8.29% | 1.79B |
- Stock Market
- Equities
- BIOVIT Stock
- News Bio Vitos Pharma AB
- YRRO Ltd agreed to acquire Hemcheck Sweden AB (OM: HEMC) in a reverse merger transaction for SEK 85.7 million.